In January 2009, the IPA was gravely concerned about the frequent reports relating to the process of examination and quality of patents in India. It also realized the consequences of inaction, as it would create jurisprudence which, in the long run, could seriously hurt the National Companies and public health.

The IPA, therefore, decided to set-up an IP Cell to examine all patent applications relating to pharmaceuticals and biopharmaceuticals published from 1st January 2009 and those which were published before 31st December 2008 but has not been processed as yet.